Your Litigation Budget Assumes One Case. Most Blockbusters Draw Five to Fifteen Simultaneous Challengers
In February, March, and April 2017, twenty-five generic drug companies sent Bristol-Myers Squibb and Pfizer formal notice that they had
The At-Risk Launch Damages Model Still Runs on 2015 Math
On September 12, 2025, a Delaware jury awarded Mallinckrodt Pharmaceuticals roughly $9.5 million against Airgas Healthcare for infringing patents covering
The At-Risk Launch Damages Model Still Runs on 2015 Math Read Post »
The Cell Therapy Manufacturing Patent Nobody Budgets For Until the CDMO Contract Falls Through
In January 2022, Lonza Walkersville and its joint-venture partner Octane Biotech sued Miltenyi Biotec in the District of Maryland, alleging
The Double Patenting Defense That Nearly Erased Tamiflu’s Last Patent
On April 22, 2014, the Federal Circuit vacated a patent infringement judgment that Gilead Sciences had already won. The drug
The Double Patenting Defense That Nearly Erased Tamiflu’s Last Patent Read Post »
mRNA Platform Patents Are Colliding. Here Is What That Means For The Next Filer
Nine separate patent holders have asserted rights against a single COVID-19 vaccine, Comirnaty, since August 2022. Two more have asserted
mRNA Platform Patents Are Colliding. Here Is What That Means For The Next Filer Read Post »
Bio-Betters Aren’t a Biosimilar Defense — They’re an Admission the Original Patent Wasn’t Strong Enough
On August 18, 2023, the FDA approved Eylea HD, Regeneron’s 8 mg reformulation of its blockbuster eye drug aflibercept. Nine
The Compulsory License Nobody Expects Until a Government Invokes It
In October 2001, the United States government came within a phone call of doing something it had never done to
The Compulsory License Nobody Expects Until a Government Invokes It Read Post »
Your US Patent Strategy Doesn’t Translate to India. That Gap Is Where the Supply Chains Get Built.
On March 20, 2026, a secondary patent covering Novo Nordisk’s semaglutide formulation expired in India. Within days, Torrent Pharmaceuticals and
Your Global Launch Sequence Assumes Uniform Patent Life. That Assumption Costs Market Share.
Samsung Bioepis launched Benepali, a biosimilar of Amgen’s Enbrel (etanercept), across the European Union on January 16, 2016 [4]. Ten
